Lead pan-coronavirus program expected to file CTA/IND in 2H 2027Optimized lead candidate shows potential for once-weekly dosing in preclinical studiesCash on balance sheet of $8.1 million at September 30, 2026
CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work
Once-Weekly Intranasal Potential: Preclinical PK data demonstrate single-dose drug levels sustained above designed therapeutic concentrations for up to 7 days in nasal mucosal and lung tissue. Addressing Endemic
HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (the "Company" or "Decoy"), today issued a correction to its press release dated September 22, 2026 announcing the
In the news release, Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding, issued 22-Sep-2026 by Decoy Therapeutics, Inc over PR Newswire, we are advised by the company
HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of
DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The spotlight is heating up across four very different high-catalyst stories: Viking Therapeutics (NASDAQ:VKTX) is pushing its VK2735 obesity program
Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design platform
Lead D-MAV demonstrates cross-viral family fusion inhibition, validating theplatform; opens a new program in filovirus pandemic preparednessCAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- Decoy Therapeutics Inc.
CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared
DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives
HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of
Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development CAMBRIDGE, Mass., June 8, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc.
CAMBRIDGE, Mass., June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target
